• Agios annual report for fiscal 2025 highlighted shift toward sustainable rare-disease commercial growth following December 2025 US clearance of AQVESME (mitapivat) for anemia in adults with alpha- or beta-thalassemia.
• US launch of AQVESME began in late January 2026, supporting push to redefine standard of care across hemolytic anemias with mitapivat franchise.
• Mitapivat expansion in sickle cell disease advanced with November 2025 Phase 3 RISE UP topline results, setting up pursuit of US accelerated approval with a supplemental New Drug Application planned in coming months.
• Global footprint broadened with PYRUKYND (mitapivat) thalassemia authorization in Saudi Arabia in August 2025, followed by United Arab Emirates in March 2026, with European Union review ongoing after positive CHMP opinion.
• Pipeline execution continued with enrollment completed for tebapivat studies in sickle cell disease, lower-risk MDS, while AG-236 in polycythemia vera moved into Phase 1 following IND clearance in June 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.